IL2 and neoplasm: Then, this cell product is reinfused back into the same patient, who have previous non-myeloablative lymphodepleting chemotherapy and subsequent cytokine therapy, like IL-2, thereby stimulating a potent anti-tumor immune response (Fig. 5).376,377 TILs enriched in specificity for neoantigens are preferable to unselected TILs at achieving complete and durable tumor regression.